Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...
FierceBiotech5d
Sanofi, Formation and OpenAI design AI tool to slash clinical trial timelines
There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.
Business Insider6d
Sanofi treatment of acute myeloid leukemia granted orphan status
A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly ...
Business Insider3d
Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application, or sBLA, for Dupixent to treat adults and ...
Morningstar3d
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
Regeneron Pharmaceuticals and Sanofi said the U.S. Food and Drug Administration has accepted their resubmitted application seeking expanded approval of the blockbuster anti-inflammatory drug ...
Seeking Alpha5d
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse drug portfolio and a robust pipeline of future drugs to market, this big ...
Business Wire5d
Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform
CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease ...
Bloomberg L.P.3d
European Stocks Fall as Traders Trim Rate-Cut Bets; Sanofi Drops
European stocks fell as traders pared back expectations for an interest-rate cut by the Federal Reserve in December after cautious comments from Chair Jerome Powell. The Stoxx Europe 600 Index was ...
pharmaphorum3d
Another big AI deal as Sanofi taps Exscientia for 15 new drugs
"Sanofi's collaboration with Exscientia aims to transform how we discover and develop new small molecule medicines for cancer and immune-mediated diseases," said the pharma group's chief ...
BioSpace5d
Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform
CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease ...
Business Weekly6d
Healx and Sanofi unite to probe new disease indications
At Healx, our mission is to ensure that no potential therapy is overlooked. “This collaboration is a testament to the strength of our platform in potentially identifying new rare disease indications ...